Bristol Myers Squibb Company BMY

62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Bristol Myers Squibb Company (BMY) Operating margin

Bristol Myers Squibb Company's operating margin over the twelve months to 30 June 2026 was 24.2%, up 4.9 percentage points from fiscal 2025 (19.4%). Over the past ten years it has ranged from −17.4% (fiscal 2024) to 30.5% (fiscal 2016); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 18.9% and above the Healthcare sector median of 0.00%.

Operating margin, annual

Annual

Period Operating margin Change (points)
FY2025 19.4% 36.71
FY2024 −17.4% (36.10)
FY2023 18.8% 2.04
FY2022 16.7% (0.75)
FY2021 17.5% 33.62
FY2020 −16.2% (35.19)
FY2019 19.0% (7.42)
FY2018 26.5% 1.75
FY2017 24.7% (5.75)
FY2016 30.5% 17.91

Quarterly

Period Operating margin Change (points)
Jun 2026 31.5% 3.31
Mar 2026 28.2% 16.42
Dec 2025 11.8% (13.71)
Sep 2025 25.5% 11.04
42 more quarters

Against its own ten years

Low −17.4% High 30.5%
Ten-year median 18.8%
Current reading's percentile 73

Operating margin against peers

Company Operating margin
NVO Novo Nordisk A/S compare 43.4%
NVS Novartis AG compare 30.2%
AMGN Amgen Inc. compare 30.0%
BMY Bristol Myers Squibb Company 24.2%
AZN AstraZeneca PLC compare 22.8%
PFE Pfizer Inc. compare 21.7%
GSK GSK PLC Sponsored ADR compare 19.6%
SNY Sanofi compare 18.2%
GILD Gilead Sciences, Inc. compare −8.20%
Drug Manufacturers General industry median 18.9%
Healthcare sector median 0.00%
Market median 0.00%

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on BMY